USPTO serial 79394695
Serial No. 79394695
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 26, 2025
- Examiner
- NEPTUNE, EVONNE MARIE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 79394695?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Robert T. Maldonado
Robert T. Maldonado Wolf, Greenfield & Sacks, P.C.600 Atlantic AvenueBoston, MA 02210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic biomarker, namely, nucleic acids, proteins in raw form, reagents, and preparations, for analytical, research and scientific use, other than for medical or veterinary purposes. | ACTIVE | — |
| 005 | Pharmaceutical and veterinary products, namely, pharmaceutical preparations for treating cancer and immune and inflammatory conditions; diagnostic products being preparations for medical use; pharmaceutical healthcare preparations for treating cancer and immune and inflammatory conditions; medicinal substances and preparations for therapeutic use, namely, for treating cancer and immune and inflammatory conditions; medical substances and preparations for the treatment and prevention of diseases, namely, for treating cancer and immune and inflammatory conditions; biochemical preparations for medical use; biological preparations for medical use, chemical preparations for medical use, namely, for treating cancer and immune and inflammatory conditions; chemical preparations for pharmaceutical use, namely, for treating cancer and immune and inflammatory conditions; biotechnological preparations for medical use, namely, for treating cancer and immune and inflammatory conditions; diagnostic preparations for medical use; in-vitro diagnostic preparations for medical use; diagnostic preparations in the nature of blood tests, namely, venipuncture for measuring nucleic acids, proteins in blood leukocytes; diagnostic kits comprising chemical reagents used for diagnostic purposes for medical use; diagnostic kits comprising reagents for diagnostic tests for medical use; health screening kits comprised of medical diagnostic reagents for screening blood and other bodily fluids and diagnosis for medical use; biological, chemical and biochemical reagents for medical use, namely, for treating cancer and immune and inflammatory conditions; diagnostic test reagents for medical or veterinary use; reagents for medical use; diagnostic reagents for medical or veterinary use; biological and chemical reagents for medical or veterinary use, namely, for treating cancer and immune and inflammatory conditions; diagnostic biomarking reagents for medical use; diagnostic biomarker reagents for analytical use for medical purposes; reagents for genetic testing for medical use and medical diagnostics; medical diagnostic test, namely, venipuncture, blood, leucocyte analysis, PCR and hybridization molecular analysis, and algorithmic analysis, and reagents for analysing blood and organic fluid; genetic identity tests comprised of reagents for medical use; diagnostic reagents and imaging contrast agents for medical use; contrast products, namely, imaging contrast agents for in-vivo imaging; cells for medical or veterinary use; biological tissue cultures for medical use; cell therapy preparations, namely, leukocytes; cell preparations for humans or animals adapted for medical or therapeutic use, namely, leukocytes. | ACTIVE | — |
| 009 | Equipment for data processing and computers; downloadable data banks in the field of human health and cancer biostatistics; downloadable computer programs for data search, collection, management, storage and analysis; data processing apparatus; downloadable software in the field of medical diagnostics for interpretation of gene and protein expression provided by diagnostic equipment; downloadable software for laboratory instruments for gene and protein expression analysis; downloadable computer software for the diagnosis of human diseases; laboratory equipment and instruments, namely, thermocyclers for research use, flow cytometers for scientific, laboratory, and general research uses; laboratory equipment and instruments for diagnostic analysis namely, thermocyclers, and flow cytometers; downloadable mobile applications for accessing, monitoring and sharing patient medical information in the field of disease diagnosis and treatment; downloadable electronic publications in the nature of medical books, magazines, brochures, and user's instruction manuals in the field of pathology, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions. | ACTIVE | — |
| 038 | Providing access to the Internet; providing online access to an electronic exchange of medical records across a nationwide health information network featuring information on the results of medical tests of patients derived from medical tests for diagnostic or treatment purposes and links to medical information; providing multiple-user access to data on the Internet in the field of medical test results of patients derived from medical tests for diagnostic or treatment purposes and medical information. | ACTIVE | — |
| 042 | Scientific and technological services for medical, biomedical and genetic purposes, namely, scientific analysis, DNA and RNA screening, and pathological testing for medical research purposes in the field of cancer and immune and inflammatory conditions as well as research and design relating thereto; industrial analysis and research services, namely, biological and molecular analyses and research; scientific and medical research and development in the field of cancer and immune and inflammatory conditions; research and development in the field of biotechnology; research in the field of chemistry and biology; research in the field of biochemistry; scientific research for medical purposes in the field of cancer and immune and inflammatory conditions; research and development in the field of diagnostic preparations; medical and scientific research in the field of cancer diagnosis and treatment; development and early evaluation of new pharmaceutical products; testing of pharmaceutical products; research and development of new products; pharmaceutical research and development services; scientific and technological services, namely, computer-aided scientific research, testing and analysis services in the field of cancer and immune and inflammatory conditions; medical and scientific research, namely, conducting clinical trials for others; conducting of scientific feasibility studies; scientific and technological services, namely, scientific analyses in the field of cancer and immune and inflammatory conditions; scientific and technological services, namely, scientific research, testing and analysis services in the field of cancer and immune and inflammatory conditions; consultant services in the field of scientific and industrial research in the field of cancer and immune and inflammatory conditions; scientific advisory and information services in the nature of preparation of reports relating to scientific research; scientific advisory and information services in the nature of preparation of scientific research and medical reports; providing information and data with respect to scientific and technological research and development in the field of cancer and immune and inflammatory conditions; providing research information and results in the field of technology, science and medicine from an online searchable database; medical and scientific research, namely, conducting clinical trials for others; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; scientific research services for third parties in the field of biotechnology; design and development of computer hardware and software; development and research of new products for third parties; consultancy services relating to biotechnology; research laboratory analysis services with respect to biotechnology, pharmacotherapy, diagnostics, pharmaceutical research and development; pharmaceutical and biological being scientific development and research services for third parties; clinical research in the field of cancer and immune and inflammatory conditions; evaluation of pharmaceutical product development, namely, screening being inspection and testing of pharmaceuticals; research in the field of pharmaceutical products; laboratory research in the field of medicinal and analytical chemistry, biology, pharmacology and toxicology; clinical research and testing services in the field of cancer and immune and inflammatory conditions; analytical laboratory services being scientific laboratory services; scientific and technological services, namely, technical analysis and scientific laboratory report drafting services for the purposes of diagnosis, prognosis and prediction of cancer and related diseases; services for the development and testing of pharmaceutical drugs; research and development of pharmaceuticals, medical devices, biotechnologies and biochemicals; technical research in the field of cancer and immune and inflammatory conditions; conducting technical studies and projects, namely scientific and clinical validation studies being cancer detection and pharmaceutical studies; computer system analysis; scientific consulting services for third parties in the field of clinical and non-clinical studies and trials on pharmaceuticals and medical devices; hosting an online website featuring computer databases in the fields of research and development of pharmaceuticals, medical devices, biotechnologies and biochemicals; hosting an online website featuring medical tests for scientific research purposes, testing for forensic research purposes, testing for quality control purposes, genetic testing for scientific research purposes, as well as medical and scientific research in the field of diseases, medical care, healthcare, pharmaceuticals, medical devices, biochemicals and biotechnology; providing, for temporary use, online non-downloadable applications and software for use in studying, diagnosing or screening for cancer and studying genetics and DNA; providing, for temporary use, online non-downloadable cloud computing software for use in studying, diagnosing or screening for cancer and studying genetics and DNA; hosting an Internet website portal in the nature of hosting an online website featuring information on the results of medical tests of patients derived from medical tests for diagnostic or treatment purposes; hosting an Internet website portal in the nature of hosting an online website featuring links to medical information. | ACTIVE | — |
| 044 | Medical services; health screening in the field of cancer and inflammatory conditions and medical diagnostic services; medical analysis services for the purposes of screening, diagnosis or treatment of cancer and prognosis of the progression of diseases; medical diagnosis of cancer and immune and inflammatory conditions; diagnosis in the field of medicine, namely cancer and immune and inflammatory conditions; medical laboratory services for the analysis of blood samples for diagnostic purposes; blood analysis services for diagnostic purposes provided by medical laboratories; medical analysis and testing services for screening, diagnostic or treatment purposes in the field of cancer; providing medical tests and reporting services for diagnostic, prognostic and predictive purposes for cancer and related diseases; providing diagnostic, prophylactic and therapeutic information in the fields of disease, medical care and healthcare; advisory services in the field of health; medical advisory services in the pharmaceutical field; medical advice concerning the preparation of diagnoses; provision of health information; providing health screening services in the field of cancer and immune and inflammatory condition, risk assessment in the field of health, customized profiles being health assessments in the field of health, and evaluation being assessment in the field of health for consumers, healthcare professionals, healthcare institutions, pharmacies and pharmaceutical product manufacturers; providing online information via an Internet website portal offering information on the results of medical tests of patients derived from medical tests for diagnostic or treatment purposes; providing information via an Internet website portal offering links to medical information. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Curzio Rüegg
- Other trademarks owned by Curzio Rüegg
- Other trademarks owned by Curzio Rüegg
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 26, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 9, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 9, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 26, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 18, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Oct 2, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 2, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 26, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 26, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 10, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 10, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 4, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 7, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 15, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 15, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 15, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 14, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 14, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 14, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 20, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 20, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 20, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 20, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 20, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 20, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 20, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 20, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 20, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 30, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 4, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 4, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 4, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 3, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 2, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 13, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 13, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 2, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |